Patents Assigned to Genentech
  • Patent number: 7807385
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: October 5, 2010
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7807799
    Abstract: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: October 5, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert L. Fahrner, Amy Laverdiere, Paul J. McDonald, Rhona M. O'Leary
  • Publication number: 20100247531
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 24, 2010
    Publication date: September 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Patent number: 7803915
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: September 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang, Chie Sakanaka, Anan Chuntharapai, Chae Janeka Reed
  • Patent number: 7803377
    Abstract: The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: September 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Minhong Yan, Yan Wu
  • Publication number: 20100239567
    Abstract: A formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.5, and an optional surfactant is described, along with uses for such a formulation.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 23, 2010
    Applicant: Genentech, Inc.
    Inventor: Osigwe Esue
  • Publication number: 20100239568
    Abstract: Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided.
    Type: Application
    Filed: April 28, 2010
    Publication date: September 23, 2010
    Applicant: GENENTECH, INC.
    Inventors: Farbod SHOJAEI, Cuiling Zhong, Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Patent number: 7799899
    Abstract: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: September 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Heidi Ackerly, Avi Ashkenazi, David Eberhard, Gretchen Frantz, Dorothy French, Germaine G. Fuh, Jo-Anne S. Hongo, Chingwei V. Lee, Scot A. Masters, Helga A. Raab, Evgeny Varfolomeev, Beni B. Wolf, Robert Maurice Pitti, Liliana Soroceanu
  • Patent number: 7799900
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Publication number: 20100233153
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO1105, PRO1279 or PRO1783 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: October 1, 2007
    Publication date: September 16, 2010
    Applicants: GENENTECH, INC., LEXICON PHARMACEUTICALS, INC.
    Inventors: Mark Dominic Borromeo, Jaime-Jo Cunningham, Frederick Desauvage, Ellen Filvaroff, Mark Alan Klamer, Laurie Jeanette Minze, Bobby Joe Payne, Carolina Rangel, Zheng-Zheng Shi, Peter Vogel
  • Publication number: 20100233121
    Abstract: Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described.
    Type: Application
    Filed: February 26, 2010
    Publication date: September 16, 2010
    Applicant: Genentech, Inc.
    Inventor: PAUL A. FROHNA
  • Publication number: 20100234576
    Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.
    Type: Application
    Filed: March 3, 2010
    Publication date: September 16, 2010
    Applicant: GENENTECH, INC.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
  • Patent number: 7795290
    Abstract: 2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: September 14, 2010
    Assignee: Genentech, Inc.
    Inventors: John K. Dickson, Jr., Carl Nicholas Hodge, Jose Serafin Mendoza, Ke Chen
  • Patent number: 7795412
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: September 14, 2010
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Publication number: 20100226880
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: October 8, 2009
    Publication date: September 9, 2010
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • Patent number: 7790858
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: September 7, 2010
    Assignee: Genentech, Inc.
    Inventor: Leonard Presta
  • Publication number: 20100221262
    Abstract: The invention provides anti-Unc5B antibodies, compositions and kits comprising the antibodies and methods of making and using the antibodies. The present invention also relates to use of anti-Unc5B antibodies to modulate angiogenesis and to treat or prevent disorders associated with abnormal angiogenesis.
    Type: Application
    Filed: November 19, 2009
    Publication date: September 2, 2010
    Applicant: Genentech, Inc.
    Inventors: Alexander W. Koch, Ryan J. Watts, Yan Wu, Anil D. Bagri
  • Patent number: 7785588
    Abstract: NTNR?, NTNR? extracellular domain (ECD), NTNR? variants, chimeric NTNR? (e.g., NTNR? immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR?-ligands, for example NTN, by providing NTNR? to the cell.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: August 31, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Patent number: 7785903
    Abstract: The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: August 31, 2010
    Assignee: Genentech, Inc.
    Inventors: Christopher J. Bond, Sachdev Sidhu
  • Patent number: 7785815
    Abstract: The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: August 31, 2010
    Assignee: Genentech, Inc.
    Inventors: David Dornan, Dorothy French, Vishva Dixit